Detection of circulating tumour necrosis factor-α after elective cardiopulmonary bypass

Abstract

Plasma samples for the assay of tumour necrosis factor-a (TNF) were obtained prior to operation, during perfusion and at hourly intervals during the first 24 hours after operation from five consecutive patients undergoing elective coronary artery bypass grafting. TNF was detected in high concentration (>10 000pg/ml) in one patient and in low levels (approximately 1 00pg/ml) in two other patients during the first 1-6 hours after removal of the aortic crossclamp at the end of perfusion. All other samples were negative. The results support the hypothesis that TNF is transiently released as a response to the endotoxaemia known to occur towards the end of bypass. The significance of these findings in relation to the development of adult respiratory distress syndrome and multiple organ failure in unstable patients undergoing open-heart surgery is discussed briefly.

Get full access to this article

View all access options for this article.

References

Ziegler Elizabeth J. Tumor necrosis factor in humans. N Engl J Med 1988; 318: 1533-35.

Michie HR , Manogue KR , Spriggs DR etal. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318: 1481-86.

Tracey KJ , Lowry SF , Cerami A. Cachectin: a hormone that triggers acute shock and chronic cachexia. J Infect Dis 1988; 157: 413-19.

Rocke DA , Gaffin SL , Wells MT , Koen Y. , Brock-Utine JG Endotoxaemia associated with cardiopulmonary bypass. J Thorac Cardiovasc Surg 1987; 93: 832-37.

Freeman R. , Wheeler J. , Robertson H. , Paes ML , Laidler J. In vitro production of TNF-α in blood samples. Lancet 1990;336:312-13.

Meager A. , Leung H. , WoolleyJ. Assays for tumour necrosis factor and related cytokines. J Immunol Methods 1989; 116: 1-17.

Maury Cpj. Tumour necrosis factor- an overview. Acta MedScand 1986; 220: 387-94.

Maury Cpj and Teppo A-M. Circulating tumour necrosis factor-α (cachectin) in myocardial infarction . J Int Med 1989;225:333-36.

Levine B. , Kalman J. , Mayer L. , Fillit HM , Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. NEnglJMed 1990; 323:236-41.

10.

Exley AR , Burman W. , Owen R. Phase I clinical trial of CB6, a murine monoclonal antibody to recombinant human tumour necrosis factor in patients with severe septic shock. Lancet 1990; 335: 1275-77.